Literature DB >> 12429903

Anthrax, MEK and cancer.

J F Bodart1, A Chopra, X Liang, N Duesbery.   

Abstract

The MEK family of protein kinases plays key roles in regulating cellular responses to mitogens as well as environmental stress. Inappropriate activation of these kinases contributes to tumorigenesis. In contrast, anthrax lethal factor, the principal virulence factor of anthrax toxin, has been demonstrated to selectively inactivate MEKs. In this article we will discuss recent advances in our understanding of molecular aspects of the pathogenesis of anthrax, emphasizing the potential role of MEK signalling in this disease, and outline novel strategies to use anthrax lethal toxin in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429903

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  7 in total

1.  Mechanisms of MAPK signalling specificity.

Authors:  L Bardwell
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

Review 2.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

3.  Treatment of ovarian cancer with modified anthrax toxin.

Authors:  Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-02       Impact factor: 12.779

4.  Anthrax lethal toxin inhibits translation of hypoxia-inducible factor 1α and causes decreased tolerance to hypoxic stress.

Authors:  Weiming Ouyang; Chikako Torigoe; Hui Fang; Tao Xie; David M Frucht
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

Review 5.  Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.

Authors:  Amir Mehdizadeh; Mohammad Hossein Somi; Masoud Darabi; Mortaza Jabbarpour-Bonyadi
Journal:  Mol Biol Rep       Date:  2016-01-14       Impact factor: 2.316

6.  MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells.

Authors:  Cristian Taccioli; Giovanni Sorrentino; Alessandro Zannini; Jimmy Caroli; Domenico Beneventano; Laura Anderlucci; Marco Lolli; Silvio Bicciato; Giannino Del Sal
Journal:  Oncotarget       Date:  2015-11-17

7.  SIRT1 increases YAP- and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma.

Authors:  Yulan Wang; Ran Cui; Xiao Zhang; Yongxia Qiao; Xiangfan Liu; Yefei Chang; Yongchun Yu; Fenyong Sun; Jiayi Wang
Journal:  Oncotarget       Date:  2016-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.